

**Perspective**

**Choosing Initial Antiretroviral Therapy: Current Recommendations for Initial Therapy and Newer or Investigational Agents**

There is general consistency among US and European guidelines regarding the initiation of antiretroviral therapy for HIV-infected individuals. Recent and ongoing trials comparing regimens may lead to reevaluation of initial treatment choices. The choice of antiretroviral regimen will also likely be affected by development, evaluation, and availability of newer drugs. This article reviews currently recommended regimens and characteristics of selected current investigational drugs, including the nucleotide analogue reverse transcriptase inhibitor tenofovir alafenamide, the nonnucleoside reverse transcriptase inhibitor doravirine, the integrase strand transfer inhibitor cabotegravir, the HIV entry inhibitor BMS-663068, and the HIV maturation inhibitor BMS-955176. This article summarizes a presentation by Roy M. Gulick, MD, MPH, at the IAS–USA continuing education program, Improving the Management of HIV Disease, held in New York, New York, in March 2015 and September 2015.

**Keywords:** HIV, antiretroviral drugs, initial therapy, tenofovir, TAF, doravirine, cabotegravir, BMS-663068, BMS-955176, CD4 attachment inhibitor, HIV maturation inhibitor

As of late 2015, 29 antiretroviral drugs are approved by the US Food and Drug Administration (FDA) for the treatment of HIV infection. Over the years, antiretroviral drugs have evolved to have greater potency, safety, and convenience in initial antiretroviral therapy regimens. A recent systematic analysis by Lee and colleagues of 114 antiretroviral therapy trials with intent-to-treat analyses and up to 3 years of follow-up through 2012 showed that the proportion of participants who achieved an undetectable viral load level on their initial antiretroviral treatment increased from 43% in the mid-1990s to more than 80% by 2010.1 The same analysis showed that the rate of participant discontinuations attributable to intolerance or toxic effects decreased from 14% to 4%, with rates of 3% or lower reported in more recent studies.2-4 Today, rates of virologic suppression of 90% or higher are being achieved among HIV-infected individuals in clinical trials and in clinical practice.4,5

An example of the improvement of antiretroviral therapy in clinical practice is provided by findings in British Columbia, Canada, where all HIV-infected individuals in the province receive treatment from a single site. The proportion of individuals receiving any antiretroviral therapy (not only initial) with plasma HIV RNA levels below 50 copies/mL increased from 65% in 2000 to 87% in 2008.6 An informal assessment survey of the HIV clinic at New York–Presbyterian/Weill Cornell Medical Center in New York, New York, indicated that approximately 90% of patients taking antiretroviral therapy had undetectable viral load levels.

**What to Start**

Initiation of antiretroviral therapy is currently recommended for essentially all HIV-infected adults regardless of CD4+ cell count or viral load.7-11 Updated guidelines from the US Department of Health and Human Services (DHHS) for initial antiretroviral therapy recommend 1) an integrase strand transfer inhibitor (InSTI)-containing regimen of dolutegravir, abacavir, and lamivudine; dolutegravir, tenofovir disoproxil fumarate (TDF), and emtricitabine; cobicistat-boosted elvitegravir, TDF, and emtricitabine; cobicistat-boosted elvitegravir, tenofovir alafenamide (TAF), and emtricitabine; or raltegravir, TDF, and emtricitabine; or 2) a protease inhibitor (PI)-containing regimen of ritonavir-boosted darunavir, TDF, and emtricitabine (Table 1).8

Current guidelines from the IAS–USA, the European AIDS Clinical Society, and the British HIV Association regarding which regimens to use for initial antiretroviral treatment variably recommend TDF and emtricitabine or abacavir and lamivudine with a third drug chosen from the nonnucleoside analogue reverse transcriptase inhibitors (NNRTIs).

**Table 1. Recommended Initial Antiretroviral Regimens From US Department of Health and Human Services Guidelines**

<table>
<thead>
<tr>
<th>InSTI-Based Regimens</th>
<th>PI-Based Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Dolutegravir, abacavir, and lamivudine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>• Darunavir boosted with ritonavir plus tenofovir disoproxil fumarate and emtricitabine&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>• Dolutegravir, tenofovir disoproxil fumarate, and emtricitabine&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>• Elvitegravir boosted with cobicistat plus tenofovir disoproxil fumarate and emtricitabine</td>
<td></td>
</tr>
<tr>
<td>• Elvitegravir boosted with cobicistat plus tenofovir alafenamide and emtricitabine</td>
<td></td>
</tr>
<tr>
<td>• Raltegravir, tenofovir disoproxil fumarate, and emtricitabine&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: InSTI, integrase strand transfer inhibitor; PI, protease inhibitor. Adapted from US Department of Health and Human Services.<sup>8</sup>

<sup>a</sup>Lamivudine and emtricitabine may be substituted for one another in these regimens.

---

Dr Gulick is Gladys and Roland Harriman Professor of Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University in New York, New York. He is a volunteer member of the Board of Directors of the IAS–USA.
Abreviations: NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor. Adapted from Department of Health and Human Services. 

Table 2. Alternative Initial Antiretroviral Regimens From US Department of Health and Human Services Guidelines

<table>
<thead>
<tr>
<th>NNRTI-Based Regimens</th>
<th>PI-Based Regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Efavirenz, tenofovir disoproxil fumarate, and emtricitabine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>- Atazanavir boosted with cobicistat plus tenofovir disoproxil fumarate and emtricitabine&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>- Rilpivirine, tenofovir disoproxil fumarate, and emtricitabine&lt;sup&gt;a&lt;/sup&gt;</td>
<td>- Atazanavir boosted with ritonavir plus tenofovir disoproxil fumarate and emtricitabine&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>- Darunavir boosted with either cobicistat or ritonavir plus abacavir and lamivudine&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>- Darunavir boosted with cobicistat plus tenofovir disoproxil fumarate and emtricitabine&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Abbreviations: NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor. Adapted from Department of Health and Human Services.

<sup>a</sup>Lamivudine and emtricitabine may be substituted for one another in these regimens.

efavirenz and rilpivirine, the ritonavir-boosted PIs atazanavir and darunavir, or the InSTIs dolutegravir, elvitegravir, and raltegravir. World Health Organization guidelines for antiretroviral treatment in resource-limited regions recommend TDF in combination with emtricitabine or lamivudine plus efavirenz. Regimens categorized as alternative by the DHHS are listed in Table 2.

Recent results from comparative trials of recommended initial regimens in HIV-infected, treatment-naïve participants may help practitioners choose from among recommended initial regimens. In the single trial, which compared once-daily abacavir and lamivudine plus dolutegravir with TDF, emtricitabine, and efavirenz, and in the FLAMINGO trial, which evaluated the once-daily regimens of dual nucleos(t)ide analogue reverse transcriptase inhibitors (nRTIs) plus dolutegravir or ritonavir-boosted darunavir, dolutegravir-containing therapy was statistically superior in terms of viral suppression rates and appeared to be better tolerated. In the SPRING-2 trial, which allowed TDF and emtricitabine or abacavir and lamivudine plus either once-daily dolutegravir or twice-daily raltegravir, dolutegravir-containing regimens were statistically noninferior.

In the AIDS Clinical Trials Group (ACTG) 5257 trial, which evaluated TDF and emtricitabine plus ritonavir-boosted atazanavir, ritonavir-boosted darunavir, or raltegravir, the raltegravir-containing regimen was superior to the 2 PI-containing regimens; additionally, the darunavir-containing regimen was superior to the atazanavir-containing regimen, owing primarily to better tolerability (mostly related to gastrointestinal symptoms and hyperbilirubinemia). These data suggest that currently recommended initial antiretroviral regimens may evolve further, and this may be reflected in future updated guidelines.

Newer or Investigational Antiretroviral Agents

Characteristics of the recently approved nRTI TAF, the investigational NNRTI doravirine (also referred to as DOR), the investigational InSTI cabotegravir (also referred to as CAB), the investigational entry inhibitor BMS-663068, and the investigational maturation inhibitor BMS-955176 are discussed below.

### Tenofovir Alafenamide

Highly desirable characteristics for a new nRTI are fewer long-term toxic effects and activity against resistant virus. The investigational nRTI TAF, like its predecessor TDF, is a prodrug of tenofovir. TDF is converted to tenofovir in plasma and then converted to tenofovir diphosphate in lymphoid cells, whereas TAF remains in prodrug form until it enters lymphoid cells, where it is also converted to tenofovir diphosphate. When TAF was developed, it was hoped that it would be associated with more efficient delivery to lymphocytes and with less drug delivery to kidney and bone, possibly decreasing toxic effects.

Combined results of 2 identical double-blind phase III noninferiority studies that compared TAF with TDF plus cobicistat-boosted elvitegravir and emtricitabine were recently published. Study 104 was conducted in North America, Europe, and Asia, and Study 111 was conducted in North America, Europe, and Latin America. The combined efficacy analysis was prespecified. Of 1753 treatment-naïve participants with HIV RNA levels of at least 1000 copies/mL and estimated glomerular filtration rates of at least 50 mL/min, 866 were randomly assigned to receive once-daily TAF and 867 were randomly assigned to receive once-daily TDF. The primary end point was the proportion of participants with HIV RNA level below 50 copies/mL; the noninferiority margin was 12% based on an FDA snapshot analysis at week 48.

Combined analysis at week 48 showed that 92% of those who received TAF versus 90% of those who received TDF achieved virologic suppression; 4% and 4%, respectively, experienced virologic failure, and for 4% and 6%, respectively, no data were available. The treatment difference between TAF and TDF was +2.0%, with a 95% confidence interval of -0.7% to +4.7% (that excluded -12.0%), thus meeting the criteria for noninferiority. Analyses of baseline viral load and CD4+ cell count subgroups showed no difference in suppression rates between study groups. In addition, TAF was associated with fewer nephrotoxic effects and less bone mineral density loss. TAF exposure has been found to substantially increase when TAF is coadministered with ritonavir-boosted atazanavir, lopinavir, or darunavir, whereas little effect has been observed when TAF is coadministered with dolutegravir or rilpivirine. There are plans for fixed-dose formulations of emtricitabine 200 mg and TAF 10 mg for concomitant use with boosted PIs or elvitegravir or TAF 25 mg for concomitant use with other InSTIs and NNRTIs. TAF was approved by the FDA in November 2015.

**Doravirine**

Desirable characteristics for a new NNRTI include fewer toxic effects and drug-drug interactions, better tolerability, and
activity against NNRTI-resistant virus strains. The investiga-
tional NNRTI doravirine is active in vitro against HIV with
NNRTI resistance–associated mutations, including K103N,
Y181C, G190A, E101K, E138K, and K103N/Y181C. Doravi-
rine is metabolized by cytochrome P450 3A4 (CYP3A4) but is
not a CYP450 inhibitor or inducer, suggesting a lower poten-
tial for drug-drug interactions. However, interactions with
rifampin have been observed, and coadministration of ri-
fampin and doravirine reduces doravirine exposure by more
than 57%. In a study of HIV-seronegative men given single
or repeated doses of doravirine, no rash or central nervous
system events were reported and pharmacokinetics sup-
ported once-daily dosing.

In a phase Ib study of 18 treatment-naive individuals, re-
ductions of HIV RNA levels of approximately 1.5 log_{10} copies/mL were observed with daily doses of doravirine 25 mg
and doravirine 200 mg given for 7 days. In a phase IIb study,
treatment-naive individuals were randomly assigned to receive TDF and emtricitabine plus efavirenz (n = 42) or
doravirine at 25 mg (n = 40), 50 mg (n = 42), 100 mg (n
= 40), or 200 mg (n = 41). At 24 weeks, an HIV RNA level of
less than 40 copies/mL was achieved in 80%, 76%, 71%, and
78% of those who received doravirine, respectively, (overall
76%) and in 64% of those who received efavirenz. At 48
weeks, the response rates were 73%, 72%, 76%, and 83% for
those who received doravirine, respectively, and 71% for those
who received efavirenz. Nausea was reported in 8% of
those who received doravirine and 2% of those in the control
group, fatigue in 7% and 5%, respectively, and diarrhea in 5%
and 10%, respectively. Doravirine 100 mg was selected for
phase III testing. At 48 weeks, the rates of toxic effects in the
central nervous system were greater among those who re-
cieved efavirenz than among those who received doravirine
100 mg (44% vs 22%, respectively; P < .001), including rates
of dizziness (28% vs 9%, respectively) and abnormal dreams
(17% vs 6%, respectively); rates of insomnia (3% vs 6%, re-
spectively) and nightmares (8% vs 6%, respectively) were
similar. Phase III studies are in progress.

Cabotegravir

A desirable characteristic of a new InSTI is less frequent dos-
ing. The investigational InSTI cabotegravir has a similar
chemical structure and resistance profile to dolutegravir but
may allow for less frequent parenteral dosing. A new inves-
tigational nanotechnologic formulation of cabotegravir may
be subcutaneously or intramuscularly injected and has a
half-life of 21 days to 50 days, supporting monthly or even
quarterly dosing (Figure 1). Adverse effects were limited to
mild injection-site reactions when single doses of this for-
mulation were studied, although nodules were observed with
subcutaneous dosing.

The pairing of long-acting parenteral drugs (ie, cabote-
gravir and rilpivirine) as maintenance antiretroviral therapy
that could be given monthly is currently being investigated.
The LATTE-1 (Long-Acting Antiretroviral Treatment Enabling
–1) study assessed the potential of maintenance therapy with
oral forms of cabotegravir and rilpivirine. In the study, 243
treatment-naive participants were randomly assigned to re-
ceive 2 nRTIs plus daily oral cabotegravir at 10 mg, 50 mg,
or 60 mg or efavirenz during an induction phase. For indi-
viduals who received cabotegravir, if HIV RNA level was less
than 50 copies/mL at 24 weeks, the 2 nRTIs were replaced
by daily oral rilpivirine 25 mg. Overall, approximately 80%
of participants who received cabotegravir achieved virologic
suppression at 24 weeks, and these responses were main-
tained to 96 weeks with oral cabotegravir plus oral rilpivirine.
The LATTE-2 study is currently evaluating oral cabotegravir
during induction therapy and parenteral cabotegravir and ril-
pivirine as maintenance therapy.

BMS-663068

Inhibition of attachment of HIV to CD4+ cells would add
a new mechanism of action to HIV treatment options. BMS-
663068 is an investigational prodrug of BMS-626529 that inhibits virus from binding to CD4+ cells by binding to HIV
envelope glycoprotein 120 (gp120). Pharmacokinetic data
support once- or twice-daily dosing of BMS-663068 without
boosting. Reduced baseline susceptibility caused by poly-
morphisms in gp120 was observed in 12% of individuals' virus
via retrospective measurement of pretreatment 50% inhibitory concentration (IC_{50}). In phase I testing, BMS-
663068 was associated with an approximately 1.5 log_{10}
reduction in HIV RNA level. In a phase IIb study, 251
treatment-experienced participants who had an IC_{50} of
the prodrug BMS-626529 of less than 100 nM received TDF and
raltegravir plus BMS-663068 400 mg or 800 mg twice daily,
BMS-663068 600 mg or 1200 mg once daily, or ritonavir-
boosted atazanavir. At week 48, an HIV RNA level below
50 copies/mL was achieved in 61% to 82% of those who
received BMS-663068 and in 71% of those who received ritonavir-boosted atazanavir, with no differences observed in response measured by baseline viral load or CD4+ cell count. BMS-663068 600 mg twice daily was selected for phase III evaluation, and heavily treatment-experienced participants are currently being enrolled in clinical trials.\(^{23}\)

**BMS-955176**

Inhibition of viral maturation would also be a novel mechanism of action in HIV treatment. A desirable characteristic of a maturation inhibitor is the absence of baseline polymorphisms that confer resistance. BMS-955176 is an oral, second-generation, investigational maturation inhibitor that acts by binding to the HIV Gag polyprotein. It exhibits greater potency and Gag polymorphism coverage than the investigational, first-generation maturation inhibitor bevirimat for which baseline resistance was seen in approximately half of individuals. Pharmacokinetics of BMS-955176 support once-daily dosing.\(^{25}\)

In a dose-escalation study of individuals who were naive to PI-containing and maturation inhibitor–containing treatment, reductions in HIV RNA level of approximately 1.5 log\(_{10}\) were achieved with 10 days of treatment with the highest doses of BMS-955176.\(^{26}\) No serious adverse events, grade 3 or 4 adverse events, or treatment-related discontinuations were observed. BMS-955176 has moved into phase II testing.\(^{27}\)

*Presented by Dr Gulick in March 2015 and September 2015. First draft prepared from transcripts by Matthew Stenger. Reviewed and edited by Dr Gulick in November 2015.*

**Financial affiliations in the past 12 months:** Dr Gulick has no relevant financial discloses to financial.

---

**References**


*Top Antivir Med*. 2015;23(4):128-131. ©2015, IAS–USA. All rights reserved.